Izotropic Secures Exclusive Rights to Patented Computer-Aided Diagnosis for Breast CT
Izotropic Corporation (OTCQB: IZOZF) has secured exclusive U.S. patent rights for computer-aided diagnosis (CADx) with breast CT technology through a global license agreement with the University of California. The company's flagship device, IzoView Breast CT Imaging System, is being developed as a 3D breast imaging solution positioned between Digital Breast Tomosynthesis (DBT) and MRI.
While IzoView will initially launch without CADx functionality, it will include a proprietary machine-learning image reconstruction algorithm that optimizes images while maintaining low radiation doses. The CADx feature will be integrated post-market launch as a software upgrade, potentially serving as an incentive for early adopters and creating future revenue opportunities.
Izotropic Corporation (OTCQB: IZOZF) ha ottenuto i diritti esclusivi per brevetto statunitense relativi alla diagnosi assistita da computer (CADx) applicata alla tecnologia di tomografia mammaria, tramite un accordo di licenza globale con l'Università della California. Il dispositivo di punta dell'azienda, IzoView Breast CT Imaging System, viene sviluppato come soluzione di imaging mammario tridimensionale posizionata tra la tomosintesi mammaria digitale (DBT) e la risonanza magnetica (MRI).
Anche se IzoView sarà lanciato inizialmente senza la funzionalità CADx, integrerà un algoritmo proprietario di ricostruzione delle immagini basato sul machine learning che ottimizza la qualità delle immagini mantenendo dosi di radiazione ridotte. La funzionalità CADx sarà aggiunta dopo il lancio sul mercato come aggiornamento software, potendo così incentivare gli early adopter e generare opportunità di ricavi future.
Izotropic Corporation (OTCQB: IZOZF) ha conseguido los derechos exclusivos de patente en EE. UU. para el diagnóstico asistido por ordenador (CADx) con tecnología de tomografía mamaria mediante un acuerdo de licencia global con la Universidad de California. El dispositivo estrella de la compañía, IzoView Breast CT Imaging System, se está desarrollando como una solución de imagen mamaria 3D situada entre la tomosíntesis digital de mama (DBT) y la resonancia magnética (MRI).
Aunque IzoView se lanzará inicialmente sin la funcionalidad CADx, incluirá un algoritmo propietario de reconstrucción de imágenes basado en aprendizaje automático que optimiza las imágenes manteniendo bajas dosis de radiación. La función CADx se integrará tras el lanzamiento al mercado como una actualización de software, lo que podría incentivar a los adoptantes tempranos y crear futuras oportunidades de ingresos.
Izotropic Corporation (OTCQB: IZOZF)는 캘리포니아 대학교와의 글로벌 라이선스 계약을 통해 유방 CT 기술의 컴퓨터 보조 진단(CADx)에 대한 미국 독점 특허권을 확보했습니다. 회사의 대표 장비인 IzoView Breast CT Imaging System은 디지털 유방 단층촬영(DBT)과 MRI의 중간 위치에 있는 3D 유방 영상 솔루션으로 개발되고 있습니다.
IzoView는 초기에 CADx 기능 없이 출시되지만, 저선을 유지하면서 영상 품질을 최적화하는 독자적인 머신러닝 기반 영상 재구성 알고리즘을 탑재합니다. CADx 기능은 출시 후 소프트웨어 업그레이드로 통합될 예정으로, 이는 초기 도입자에 대한 유인책이자 향후 수익 창출 기회가 될 수 있습니다.
Izotropic Corporation (OTCQB: IZOZF) a obtenu les droits exclusifs du brevet américain pour le diagnostic assisté par ordinateur (CADx) appliqué à la technologie CT mammaire, via un accord de licence mondial avec l'Université de Californie. Le dispositif phare de la société, le IzoView Breast CT Imaging System, est en cours de développement comme solution d'imagerie mammaire 3D positionnée entre la tomosynthèse mammaire numérique (DBT) et l'IRM.
Bien qu'IzoView soit lancé initialement sans la fonctionnalité CADx, il intégrera un algorithme propriétaire de reconstruction d'images fondé sur l'apprentissage automatique qui optimise les images tout en maintenant de faibles doses de radiation. La fonction CADx sera intégrée après le lancement commercial sous forme de mise à jour logicielle, ce qui pourrait inciter les premiers utilisateurs et créer de futures opportunités de revenus.
Izotropic Corporation (OTCQB: IZOZF) hat über eine globale Lizenzvereinbarung mit der University of California exklusive US-Patentrechte für computerunterstützte Diagnostik (CADx) in Verbindung mit Brust-CT-Technologie gesichert. Das Flaggschiff des Unternehmens, das IzoView Breast CT Imaging System, wird als 3D-Brustbildgebungslösung entwickelt, die zwischen der digitalen Brust-Tomosynthese (DBT) und der MRT angesiedelt ist.
Obwohl IzoView zunächst ohne CADx-Funktionalität auf den Markt kommt, wird es einen proprietären, maschinellen Lernalgorithmen zur Bildrekonstruktion enthalten, der Bilder bei gleichzeitiger Aufrechterhaltung niedriger Strahlendosen optimiert. Die CADx-Funktion wird nach Markteinführung als Software-Upgrade integriert, was Early Adopter anreizen und zukünftige Umsatzmöglichkeiten schaffen könnte.
- Secured exclusive U.S. patent rights for CADx with breast CT technology
- Proprietary machine-learning algorithm optimizes images while maintaining low radiation doses
- Future revenue potential through post-market CADx software upgrades
- Strategic positioning between DBT and MRI in breast imaging market
- IzoView will not include CADx feature at initial launch
- Additional market authorizations required for CADx integration
- U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT -
- Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement -
- CADx upgrade to be integrated into IzoView Breast CT post-initial market launch, feature may be offered as an upgrade incentive to early adopters -
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announced the issuance of the only U.S. patent for computer-aided diagnosis with breast CT, covered by the Company’s exclusive global license agreement to breast CT technology with the Regents of the University of California.
Computer-aided diagnosis (“CADx”) is an AI software-based tool used in radiology to support physicians in interpreting medical images by analyzing them to estimate the likelihood of malignancy. In breast imaging, CADx has become an area of focus to address the limitations of various imaging modalities, improve diagnostic performance, and support radiologists in making faster, more confident decisions. For example, mammography, digital breast tomosynthesis (“DBT”), and ultrasound can miss cancers due to overlapping tissue, breast density, or operator variability. CADx is being developed to address these limitations by flagging subtle abnormalities that may be missed during initial review. These systems aim to improve cancer detection in cases where the imaging modality itself may not fully visualize an abnormality. In MRI, CADx can play a different but equally important role. MRI, like breast CT, produces larger volumes of detailed imaging data that therefore take more time to interpret. CADx is being increasingly used to support radiologists by triaging exams, highlighting abnormal regions, and reducing read times to improve overall efficiency. In all applications, CADx is being developed to support more consistent interpretation, reduce diagnostic uncertainty, and streamline clinical workflows.
Izotropic’s flagship device, the IzoView Breast CT Imaging System, is being commercialized as a powerful, true 3D breast-dedicated imaging alternative that bridges the gap between DBT and MRI, with an initial Indication for Use with contrast-enhancement for adjunctive breast cancer screening in asymptomatic patients with dense breast tissue.
While IzoView will not initially launch with a CADx feature, it will go-to-market with the integration of a trade-secret machine-learning image reconstruction algorithm developed for real-world clinical workflows that optimizes IzoView’s images by addressing CT imaging noise while overcoming the limitations of existing methods, and maintaining low radiation doses comparable to 2-view mammography.
The Company plans to integrate CADx into IzoView as a post-market feature, available via software upgrade after additional market authorizations. The feature may be offered as an incentive to early adopters, supporting clinical value while contributing to future software-based revenue opportunities.
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What patent rights did Izotropic (IZOZF) secure for breast CT technology?
When will the CADx feature be available in IzoView Breast CT?
What are the key features of Izotropic's IzoView Breast CT system at launch?
How does IzoView Breast CT position itself in the breast imaging market?
What is the potential business impact of the CADx feature for Izotropic (IZOZF)?
